Carnitine for fatigue in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 5, 2012, Pages

  Tejani, Aaron M ^a   Wasdell, Michael ^b   Spiwak, Rae ^c   Rowell, Greg ^a   Nathwani, Shabita ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FRASER HEALTH AUTHORITY   (Canada)

^c Burnaby Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; AMANTADINE; VITAMIN B COMPLEX;

ADULT; FATIGUE; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ACETYLCARNITINE; ADULT; AMANTADINE; FATIGUE; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84864522311     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007280.pub3     Document Type: Article

References (47)

1. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal Neurological Sciences 2004;218(1-2):103-8.
2. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis 2006;12(3):321-4.
3. Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis (FACTSEP). Ongoing study June 2010.
4. Branas P, Jordan RE, Fry-Smith A, Burls A, Hyde CJ. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000;4:27.
5. Ciacci C, Peluso G, Iannoni E, Sinisgalchi M, Iovino P, Rispo A, et al. L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. Digestive Liver Disease 2007;39(10):922-8.
6. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Annals of the New York Academy of Sciences 2004;1033:168-76.
7. Cylert (package insert). Abbott Laboratories: East Chicago, Illinois 1999.
8. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences 1994;21:9-14.
9. Flensner G, Lindencrona C. The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis. Journal of Advanced Nursing 2002;37:541-50.
10. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Archives of Physical Medicine and Rehabilitation 1984;65:135-8.
11. Fukazawa T, Sasaki H, Kikuchi S, Hamada T, Tashiro K. Serum carnitine and disabling fatigue in multiple sclerosis. Psychiatry and Clinical Neurosciences 1996;50(6):323-325.
12. Gillson G, Richard TL, Smith RB, Wright JV. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Multiple Sclerosis 2002;8:30-5.
13. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. British Journal of Cancer 2002;86:1854-7.
14. Helman A. Carnitine for Alzheimer's Disease. Arbor Clinical Nutrition Updates 2005;230:1-2.
15. Iriarte J, Katsamakis G, de Castro P. The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Multiple Sclerosis 1999;5:10-16.
16. Jackson MF, Quaal C, Reeves MA. Effects of multiple sclerosis on occupational and career patterns multiple sclerosis on occupational and career patterns. Axone 1991;13:16-17.
17. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. Journal of Neurological Sciences 2002;205:51-8.
18. Kos D, Kerckhofs E, Nagels G, D'hooghe MB, Llsbroukx S. Origin of Fatigue in Multiple Sclerosis: Review of the Literature. Neurorehabilitation and Neural Repair 2008;22:91-100.
19. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Archives of Neurology 1988;45:435-7.
20. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45:1956-61.
21. Laviano A, Mequid MM, Guijarro A, Muscaritoli M, Cascino A, Preziosa I, et al. Antimyopathic Effects of Carnitine and Nicotine. Current Opinion in Clinical Nutrition and Metabolic Care 2006;9(4):442-8.
22. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Multiple Sclerosis 2006;12:321-4.
23. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
24. Malaguarnera M, Callamerri L, Gargante MP, Vacante M, Colonna V, Motta M. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. American Journal of Clinical Nutrition 2007;86:1738-44.
25. Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemotherapy Pharmacology 1999;44:170-2.
26. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302. [MEDLINE: 11456302]
27. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Multiple Sclerosis 2002;8:161-8.
28. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences 1985;12:251-4.
29. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. Journal of Cell Physiology 2000;182:339-50.
30. Pistone G, Marino AD, Leotta C, Dell'Arte S, Finocchario G, Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue. Drugs Aging 2003;20:761-7.
31. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997;35:16-23.
32. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic Criteria for Multiple Sclerosis: 2005 revisions to the Macdonald Criteria. Annals of Neurology 2005;59(4):840-6.
33. Poser CM, Paty DW, Scheinberg L, Mc Donald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for Multiple Sclerosis: guide-lines for research protocols. Annals of Neurology 1983;13(3):227-31.
34. Pucci E, Branas P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2]
35. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Paralyzed Veterans of America 1998.
36. Racke MK, Hawker K, Frohman EM. Fatigue in Multiple Sclerosis: is the picture getting simpler or more complex?. Archives of Neurology 2004;61:176-7.
37. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study. Journal of Neurologu, Neurosurgery and Psychiatry 2002;72:179-83.
38. Rossini M, Di Munno O, Valentini G, Bianchi G, Cacace E, et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clinical and Experimental Rheumatology 2007;25(2):182-8.
39. Sa, Jose Maria. Psychological aspects of multiple sclerosis. Clinical Neurology and Neurosurgery November 2008;110(9):868-877.
40. Sayed-Ahmed MM, Shaarawy S, Shouman SA, Osman AMM. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacological Research 1999;39:289-95.
41. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell, et al. Problems of experimental trials of therapy in Multiple Sclerosis: Report by the panel of the evaluation of experimental trials in Multiple Sclerosis. Annals of the New York Academy of Sciences 1965;122:552-68.
42. Schwid S, Covington M, Segal B, Goodman A. Fatigue in multiple sclerosis: Current understanding and future direction. Journal of rehabilitation Research and Development 2002;39:211-24.
43. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001330]
44. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Fatigue in Multiple Sclerosis Persists Over Time: a longitudinal study. Journal of Neurology 2006;253:1466-70.
45. United Kingdom Multiple Sclerosis Society. Symptom Management Survey. United Kingdom Multiple Sclerosis Society 1997.
46. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GPA. A double-blind, randomized crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42:1468-71.
47. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. Journal of Neurology 2002;249:983-7.